1RedLANO e–Journal2 0 1 2www.redlano.org( E p u b a h e a d o f p r i n t )Ciencias básicasDuncan, C. G. et. al. A heteroz...
2RedLANO e–Journal2 0 1 2www.redlano.org( E p u b a h e a d o f p r i n t )Wu, G. et. al. Somatic histone H3 alterations i...
3RedLANO e–Journal2 0 1 2www.redlano.org( E p u b a h e a d o f p r i n t )Falchook, G. S. et. al. Dabrafenib in patients ...
4RedLANO e–Journal2 0 1 2www.redlano.org( E p u b a h e a d o f p r i n t )Linfoma del sistema nervioso centralGhesquières...
Upcoming SlideShare
Loading in …5

Lecturas recomendadas neuro oncología 2012


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Lecturas recomendadas neuro oncología 2012

  1. 1. 1RedLANO e–Journal2 0 1 2www.redlano.org( E p u b a h e a d o f p r i n t )Ciencias básicasDuncan, C. G. et. al. A heterozygous IDH1R132H/WT mutationinduces genome-wide alterations in DNA methylation. Geno-me Res. 2012 Dec;22(12):2339-55.Lu, C. et. al. IDH mutation impairs histone demethylationand results in a block to cell differentiation. Nature. 2012 Feb15;483(7390):474-8.Sturm, D. et. al. Hotspot mutations in H3F3A and IDH1 definedistinct epigenetic and biological subgroups of glioblastoma.Cancer Cell. 2012 Oct 16;22(4):425-37.Turcan, S. et. al. IDH1 mutation is sufficient to establish theglioma hypermethylator phenotype. Nature. 2012 Feb15;483(7390):479-83.Chen, J. et. al. A restricted cell population propagates glio-blastoma growth after chemotherapy. Nature. 2012 Aug23;488(7412):522-6.Friedmann-Morvinski, D. et. al. Dedifferentiation of neuronsand astrocytes by oncogenes can induce gliomas in mice.Science. 2012 Nov 23;338(6110):1080-4.Muller, F. L. et. al. Passenger deletions generate therapeuticvulnerabilities in cancer. Nature. 2012 Aug 16;488(7411):337-42.LECTURAS RECOMENDADAS NEURO–ONCOLOGÍA 2012Sasaki, M. et. al. IDH1(R132H) mutation increases murine hae-matopoietic progenitors and alters epigenetics. Nature. 2012Aug 30;488(7413):656-9.Singh, D. et. al. Transforming fusions of FGFR and TACC genesin human glioblastoma. Science. 2012 Sep 7;337(6099):1231-5.Snuderl, M. et. al. Mosaic amplification of multiple receptortyrosine kinase genes in glioblastoma. Cancer Cell. 2011 Dec13;20(6):810-7.Vivanco, I. et. al. Differential sensitivity of glioma- versus lungcancer-specific EGFR mutations to EGFR kinase inhibitors.Cancer Discov. 2012 May;2(5):458-71.Koivunen, P. et. al. Transformation by the (R)-enantiomer of2-hydroxyglutarate linked to EGLN activation. Nature. 2012Feb 15;483(7390):484-8.Neuro-oncología pediátricaJones, D. T. et. al. Dissecting the genomic complexi-ty underlying medulloblastoma. Nature. 2012 Aug2;488(7409):100-5.Northcott, P. A. et. al. Subgroup-specific structural variationacross 1,000 medulloblastoma genomes. Nature. 2012 Aug2;488(7409):49-56.
  2. 2. 2RedLANO e–Journal2 0 1 2www.redlano.org( E p u b a h e a d o f p r i n t )Wu, G. et. al. Somatic histone H3 alterations in pediatricdiffuse intrinsic pontine gliomas and non-brainstem glio-blastomas. Nat Genet. 2012 Jan 29;44(3):251-3.Robinson, G. et. al. Novel mutations target distinct subgroupsof medulloblastoma. Nature. 2012 Aug 2;488(7409):43-8.Schwartzentruber, J. et. al. Driver mutations in histone H3.3and chromatin remodelling genes in paediatric glioblasto-ma. Nature. 2012 Jan 29;482(7384):226-31.Patología en tumores cerebralesJiao, Y. et. al. Frequent ATRX, CIC, and FUBP1 mutations refi-ne the classification of malignant gliomas. Oncotarget. 2012Jul;3(7):709-22.Liu, X. Y. et. al. Frequent ATRX mutations and loss of expres-sion in adult diffuse astrocytic tumors carrying IDH1/IDH2and TP53 mutations. Acta Neuropathol. 2012 Aug 12.Lu, K. V. et. al. VEGF inhibits tumor cell invasion and mesen-chymal transition through a MET/VEGFR2 complex. CancerCell. 2012 Jul 10;22(1):21-35.CirugíaCastellano, A. et. al. Role of diffusion tensor magnetic reso-nance tractography in predicting the extent of resection inglioma surgery. Neuro Oncol. 2012 Feb;14(2):192-202.De Witt Hamer, P. C. et. al. Impact of intraoperative stimu-lation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012 Jul 10;30(20):2559-65.Gans, J. H. et. al. The Role of Radiosurgery to the Tumor BedAfter Resection of Brain Metastases. Neurosurgery. 2012 Nov30.Hofmann, B. M. et. al. Results after treatment of craniopharyn-giomas: further experiences with 73 patients since 1997. JNeurosurg. 2012 Feb;116(2):373-84.RadioterapiaTsien, C. I. et. al. Concurrent temozolomide and dose-esca-lated intensity-modulated radiation therapy in newly diag-nosed glioblastoma. Clin Cancer Res. 2012 Jan 1;18(1):273-9.Pallud, J. et. al. Dynamic imaging response following radia-tion therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol. 2012 Apr;14(4):496-505.Metastasis cerebralesSoffietti, R. et. al. A European Organisation for Research andTreatment of Cancer Phase III Trial of Adjuvant Whole-BrainRadiotherapy Versus Observation in Patients With One toThree Brain Metastases From Solid Tumors After Surgical Re-section or Radiosurgery: Quality-of-Life Results. J Clin Oncol.2013 Jan 1;31(1):65-72.
  3. 3. 3RedLANO e–Journal2 0 1 2www.redlano.org( E p u b a h e a d o f p r i n t )Falchook, G. S. et. al. Dabrafenib in patients with melanoma,untreated brain metastases, and other solid tumours: a phase1 dose-escalation trial. Lancet. 2012 May 19;379(9829):1893-901.Long, GV. et. al. Dabrafenib in patients with Val600Glu orVal600Lys BRAF-mutant melanoma metastatic to the brain(BREAK-MB): a multicentre, open-label, phase 2 trial. LancetOncol. 2012 Nov;13(11):1087-95.Margolin, K. et. al. Ipilimumab in patients with melanomaand brain metastases: an open-label, phase 2 trial. LancetOncol. 2012 May;13(5):459-65.Preusser, M. et. al. Trial design on prophylaxis and treatmentof brain metastases: Lessons learned from the EORTC Bra-in Metastases Strategic Meeting 2012. Eur J Cancer. 2012Dec;48(18):3439-47.Tsao, M. N. et. al. Radiotherapeutic and surgical manage-ment for newly diagnosed brain metastasis(es): An Ameri-can Society for Radiation Oncology evidence-based gui-deline. Practical Radiation Oncology. 2012; 2(3): 210-225.http://download.journals.elsevierhealth.com/pdfs/jour-nals/1879-8500/PIIS1879850011003808.pdfGliomas de alto gradoCairncross G, et. al Phase III Trial of Chemoradiotherapy forAnaplastic Oligodendroglioma: Long-Term Results of RTOG9402. J Clin Oncol. 2012 Oct 15. [Epub ahead of print]Van den Bent MJ, et. al. Adjuvant Procarbazine, Lomustine,and Vincristine Chemotherapy in Newly Diagnosed Ana-plastic Oligodendroglioma: Long-Term Follow-Up of EORTCBrain Tumor Group Study 26951. J Clin Oncol. 2012 Oct 15.[Epub ahead of print]Malmström A. et. al. Temozolomide versus standard 6-weekradiotherapy versus hypofractionated radiotherapy in pa-tients older than 60 years with glioblastoma: the Nordic ran-domised, phase 3 trial. Lancet Oncol. 2012 Sep;13(9):916-26.Wick, W. et. al. Temozolomide chemotherapy alone versusradiotherapy alone for malignant astrocytoma in the elderly:the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub2012 May 10.Gliomas de bajo gradoJakola, A. S. et. al. Comparison of a strategy favoring earlysurgical resection vs a strategy favoring watchful waiting inlow-grade gliomas. JAMA. 2012 Nov 14;308(18):1881-8.Pallud, J. et. al. Quantitative morphological magnetic reso-nance imaging follow-up of low-grade glioma: a plea forsystematic measurement of growth rates. Neurosurgery.2012 Sep;71(3):729-39; discussion 739-40.Potts, M. B. et. al. Natural history and surgical managementof incidentally discovered low-grade gliomas. J Neurosurg.2012 Feb;116(2):365-72.Englot, D. J. et. al. Extent of surgical resection predicts seizu-re freedom in low-grade temporal lobe brain tumors. Neuro-surgery. 2012 Apr;70(4):921-8.
  4. 4. 4RedLANO e–Journal2 0 1 2www.redlano.org( E p u b a h e a d o f p r i n t )Linfoma del sistema nervioso centralGhesquières H, et. al. Evidence of time-dependent prognos-tic factors predicting early death but not long-term outco-me in primary CNS lymphoma: a study of 91 patients. Hema-tol Oncol. 2012 Aug 9.Gonzalez-Aguilar A, et. al. Recurrent mutations of MYD88and TBL1XR1 in primary central nervous system lymphomas.Clin Cancer Res. 2012 Oct 1;18(19):5203-11.Mappa S, et. al. Salvage chemoimmunotherapy with rituxi-mab, ifosfamide and etoposide (R-IE regimen) in patientswith primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol.2012 Nov 14.Roth P, et. al. Outcome of elderly patients with primary CNSlymphoma in the G-PCNSL-SG-1 trial. Neurology. 2012 Aug28;79(9):890-6.Welch MR, et. al. Outcomes of the oldest patients with pri-mary CNS lymphoma treated at Memorial Sloan-KetteringCancer Center. Neuro Oncol. 2012 Oct;14(10):1304-11.Cuidados y soporte paliativo en neuro-oncologíaChochinov, H. M. et. al. The Patient Dignity Inventory:applications in the oncology setting. J Palliat Med. 2012Sep;15(9):998-1005.Colen, C. B. and Allcut, E. Quality of life and outcomes inglioblastoma management. Neurosurg Clin N Am 23 (2012)507-513.Efficace, F. and Taphoorn, M. Methodological issues in de-signing and reporting health-related quality-of-life in cancertrials: the challenge of brain cancer studies. J Neurooncolo-gy (2012) 108: 221-226Ford, E. et. al. Systematic review of supportive care needsin patients with primary malignant brain tumours. Neuro-Oncology 14 (4): 392-404, 2012Gofton, T. E. et. al. Identifying the palliative care needs ofpatients living with cerebral tumours and metastases : a re-trospective analysis. J Neurooncology (2012) 108: 527-534de Groot, M. et. al. Epilepsy in patients with a brain tumour:focal epilepsy requires focused treatment. Brain. 2012Apr;135 (Pt4):1002-16.Rooney, A. G. et. al. Frequency, clinical associations, and lon-gitudinal course of major depressive disorder in adults withcerebral glioma. J Clin Oncol. 2011 Nov 10;29(32):4307-12.